Emotional and Cognitive Aspects of PD

The Parkinson’s Disease Foundation (PDF) hosted a symposia on Parkinson’s on July 18, 2008.  The overall topic is “Mind, Mood and Body: Understanding Nonmotor Symptoms of PD.”  Here’s a link to the archived recording of the symposia:

event.netbriefings.com/event/pdf/Archives/nonmotor/register.html

The second speaker, Dr. Matthew Menza, gave a good presentation on the topic of “Emotional and Cognitive Aspects of Parkinson’s Disease.”

Even though this presentation was focused on PD, some references are made to LBD.  And, of course, there are emotional and cognitive aspects to all of the atypical parkinsonism disorders.

The most important thing I got from Dr. Menza’s presentation is that SSRIs should *not* be considered as the first line treatment in dealing with depression in PD.  A recent study showed that an old antidepressant, nortriptyline (Pamelor), performed better than Paxil, an SSRI.  Other drugs that are similar to nortriptylnie are Cymbalta and Effexor.

Of the atypical parkinsonism disorders, the only antidepressant that has been studied is Elavil (amitriptyline) in PSP.  Otherwise, I’m not aware of any studies.  You might take this recent PD research to your MD to find out if his/her recommendation would change based upon the new info.

Dr. Menza spent some amount of time on antipsychotics.  He explained that there was good data to recommend Clozaril and that in some studies Seroquel performed no better than the placebo.

He did talk about Lewy Body Dementia a couple of times, but I didn’t think his description was very good.  (Dr. Menza is a neurologist and psychiatrist.)

These are my notes from his presentation and his answers to the questions directed to him.  Of course it’s much better to watch the video yourself.

Robin


Robin’s notes from:

Emotional and Cognitive Aspects of Parkinson’s Disease
Matthew Menza, M.D., Prof. of Psychiatry and Neurology, Robert Wood Johnson Medical School

Non-motor symptoms of PD include:
* sleep disturbances, fatigue, and excessive daytime sleepiness
* depression
* drug reactions, including psychosis and impulsivity
* mild cognitive impairment to dementia

The non-motor symptoms have become the focus of research because they are so important to how patients feel day to day.

Depression:  about 40% have some.  It has a major impact on quality of life and functioning (faster progression of motor symptoms; greater decline in cognitive skills; greater decline in ability to care for self).  Depression often precedes the PD diagnosis.

Symptoms of depression include:  sadness, lack of appetite, sleep problems, lack of interest and motivation, fatigue, crying spells, etc.  Some of these symptoms are seen in PD without depression.  (6:22)

Depression is very inter-related with anxiety (worrying about things in an excessive way).  Anxiety is a common symptom in PD.

What causes depression in PD?  Probably a mix of neurochemical changes in the brain that accompany PD and the stress of living with an illness.

We encourage people to get involved in support groups.  There’s a lot of knowledge in SGs about handling day to day problems.  SG members may have common wisdom that MDs may not know about.

Try relaxation techniques to help yourself forget worries and get to sleep.  Even counting sheep.

Psycho-therapies are being modified and written expressively for those with PD.  Best to find a psychiatrist or psychologist who has experience with PD.

Exercise is a good treatment for depression.

NIH funded an 8-week trial of PD and paroxetine CR (an SSRI), nortriptyline (a tricyclic), and placebo.  This is the largest and first of placebo-controlled studies on antidepressants and PD.  This study is not yet published.  (Other studies are in the works.)  Big improvement in depression for both anti-depressants but nortriptyline was much better than paroxetine.  [paroxetine CR = Paxil CR; nortriptyline = Pamelor]  Nortriptyline affects both serotonin and norepinephrine in the brain.  Paroxetine affects only serotonin.  This study calls into question the use of SSRIs as first line treatment in PD.  Two other newer drugs that affect both serotonin and norepinephrine are Cymbalta and Effexor.  Paxil was effective for some in the study.  (23:48)

Sleep problems in PD are more common than would be expected from age alone.  50-75% of people with PD have trouble with sleep.  In their current study, sleep was the #1 predictor of quality of life (even more than motor problems).  The most common sleep problem is difficulty staying asleep (74-88% of patients).  Other problems:  poor quality sleep, difficulty falling asleep, muscle movements (PLMS and RLS; up to 15%), sleep apnea (up to 12%), RBD, morning headaches.

RBD (REM behavior disorder) is a particular concern.  PD accounts for 27% of RBD cases.  32% had injured themselves and 64% had assaulted their spouse.  Acting out dreams.  Can be a few vocalizations or something more dramatic.  People are reluctant to talk to MDs about this.  There’s a good treatment for RBD that works most of the time.

Excessive daytime sleepiness (EDS) occurs in up to 51% of PD patients.

Sleep attacks (sudden onset of sleep, usually without much warning) are associated with nearly every dopaminergic medication but especially Mirapex and Requip.  3.8% of PD patients had sudden attacks while driving.  Some still debate whether these attacks are caused by these drugs or EDS.

Sleep disturbances in PD may be related to nocturia (frequent need to urinate at night), pain, dystonia, akinesia, difficulty turning, etc.  Sleep is regulated by adrenergic, serotonergic, cholinergic, and various peptidergic symptoms which are disrupted (variably) in PD.  Depression is a major risk factor.  Dopaminergics can also worsen sleep (produce arousal and suppress REM).  (33:00)

Treatment of sleep disturbances includes:  exercise, sleep hygiene, intermittent use of sleep meds (Lunesta, Ambien, etc).  Some medications may help daytime sleepiness including Provigil, Ritalin (an older stimulant), and sometimes amantadine (Symmetrel).

Sleep hygiene:  regular sleep hours; avoid excess time in bed; regular get-up time regardless of sleep quality; avoid daytime naps (of 2 hours in length; 15 minutes is OK); use bed for sleep or sex; relaxation; physical activity; sunlight in morning; bedroom quality (noise, temperature, humidity); avoid evening stimulants; avoid large evening meals.  If you are worrying, get out of bed.  (36:34)

Two categories of unusual behaviors that sometimes accompany meds given for PD:  psychosis (hallucinations and delusions); impulse control disorders (including gambling, binge eating, buying, hypersexuality).

Psychosis is rare in untreated PD.  Can be caused by all PD meds though psychosis is somewhat more frequent with dopaminergic receptor agonists.  Biggest risk factor for developing psychosis is memory impairment.

Hallucinations (seeing something that isn’t really there) occurs in approximately 30% of PD patients.  Usually these are mild.  The problem is when hallucinations are frightening.

Delusions (belief that isn’t shared by other people in your world) occur in 3-17% of patients.  Can cause major problems and be very disruptive.  Generally later in illness when memory begins to fail.  Typically persecutory (eg, fear of being poisoned, infidelity).  Please bring these up with your MD.

There was just a large study on impulse control behaviors just discussed.  Seem to occur more frequently with Mirapex and Requip but can also occur with Sinemet.  (42:03)

In the face of these problems (psychosis or impulse control disorders), the first thing MDs do is reduce the dopamine medication.  “Motion-emotion conundrum.”  If reducing the parkinson meds doesn’t solve the problem, then MDs look to antipsychotics.  (43:08)  The first antipsychotic given is Seroquel.  If that doesn’t work, then Clozaril is tried.  Clozaril requires a weekly blood sample.  Clozaril is very effective.  (43:42)

In early PD, most develop a little of what could be described as “mild cognitive impairment.”  This is impairment of tasks requiring the frontal lobe of the brain — planning, judgment, and recall memory.  This doesn’t cause major problems.  Dopamine replacement leads to some improvement.  (44:39)

The more difficult thing is the more serious memory impairment that happens later in the disease.  Quite a few people develop this.  This is not Alzheimer’s.  This is much, much slower in development than Alzheimer’s, and generally less severe.  There are trials out there looking at the typical AD drugs (such as Exelon) in PD.  In one study, Exelon had a slightly positive response, and some with PD can take this drug.  It’s worth trying.  There is a question if Namenda will work.

Dealing with cognitive impairment includes:  household safety (and preventing wandering), reminders as to the structure of the house, day care, in-home help.

It’s important to educate yourself about psychiatric issues.  Sometimes you have to educate your physician about psychiatric issues in PD.  (46:39)

Question: Is bipolar a precursor to PD?
Answer:  I don’t think so but on the other hand certainly people with PD can develop bipolar disorder (though this would be unusual).  Bipolar disorder hits people early in life.  (48:00)

Question:  Can you elaborate on Lewy bodies?
Answer:  In Lewy body disease, there is wide distribution of Parkinson’s pathology across the brain.  This is a variant of PD where the cognitive impairment and memory impairment progresses much, much more rapidly than in normal PD.  And the individuals are much more sensitive to the adverse side effects of PD.  It’s a much more rapidly progressive illness than normal PD.  Not much is known about LBD.  It can be quite a trial.  (49:10)

Question:  What were the side effects related to nortriptyline?  (50:06)
Answer:  The newer antidepressants are better tolerated.  Surprisingly, nortriptyline (an older med) was well tolerated.  There was more constipation in the nortriptyline group.  Our lesson from the study:  don’t start with an SSRI.  (51:13)

Question:  When will a cure happen?
Answer:  Someday there will be a cure.  But what do you do now?  We need research on the problems we are having right now.  (51:56)

Question:  Can you comment on the French clozapine study?
Answer:  There have been two well-controlled Clozaril trials showing Clozaril is better than placebo for psychosis.  Weekly blood draws for six months can be a problem for some.  Some of the Seroquel trials did not show that Seroquel was any better than placebo.

Question:  Can we view panic reactions as a behavioral equivalent of a motor tremor?
Answer:  I suppose you could look at them that way.  Sometimes those with anxiety have panic attacks.  I don’t know if it’s the same neurochemically.

Question:  Depression vs. anger.  Can anger be a stimulus?
Answer:  Anger can motivate people to make changes in behavior.  If people are having a lot of anger, it’s usually based on relationships and chronic problems.  Counseling may be helpful in determining cause of anger.  Is the anger a personality change?

Question:  What determines sexual dysfunction?  Compared to what you used to do?  Frequency?
Answer:  These problems are happening in people who are older, some of whom have less interest in sex.  Autonomic dysfunction can contribute.  There are also relationship issues.  If something has dramatically changed compared to the past, then we look to some cause (medication?) for the problem.  (56:09)

Question:  If a person with PD is on bipolar meds, and needs an antidepressant, is there a conflict?  Are they more likely to become manic?  Any connection?
Answer:  This is complicated.  Lithium (a bipolar med) can sometimes not be at all well-tolerated in PD.  Med changes have to be made.  But there are some bipolar meds that those with PD can take.  Depression would be seen as a function of bipolar disorder.  In bipolar disorder, we generally try not to use antidepressants because this can worsen the mania.  But we do use them in conjunction with a mood stabilizer.  (58:10)

Question:  My husband becomes agitated and anxious.
Answer:  Agitation can be many things.  Impulsivity can be a personality change.  Is there a change in impulsivity?

Question:  How effective is Remeron for depression in PD?
Answer:  We have no idea.  Remeron is a new kind of antidepressant.  It works differently than Paxil, Prozac, that class.  Remeron tends to be very helpful with sleep.  It has a lot of antihistaminic and anticholinergic effects so it can make constipation worse.  Each antidepressant needs to be studied individually:  does this drug work in this person?

Question:  Is depression in PD hereditary?  (00:48)
Answer:  We don’t know.  We think that in non-PD depression has a hereditary component (“somewhat more likely” to develop PD).  Many people, however, with no family history develop depression, and many people with a family history of depression who never develop it.  Is there something different about PD and depression compared to PD without depression?  We don’t know but it’s a good question.

 

GI, Urological, Sexual and Other Functions – Dr. Pfeiffer’s talk

The Parkinson’s Disease Foundation (PDF) hosted a symposia on Parkinson’s on July 18, 2008.  The overall topic is “Mind, Mood and Body: Understanding Nonmotor Symptoms of PD.”  Here’s a link to the archived recording of the symposia:

event.netbriefings.com/event/pdf/Archives/nonmotor/register.html

The first speaker, Dr. Ron Pfeiffer, gave a wonderful presentation on the topic of “When Parkinson’s Interferes with Gastrointestinal, Urological, Sexual and Other Functions.”

Even though this presentation was focused on PD, lots of references are made to MSA.  And, of course, GI, urological, and other symptoms appear in all of the atypical parkinsonism disorders.

I’d heard Dr. Pfeiffer speak twice previously.  There was one new item from him:  To treat irritative urinary symptoms, he prefers the newer anticholinergics (Sanctura, Enablex, Vesicare — the first two are unlikely to cross the blood-brain barrier) compared to the older ones (Ditropan, Detrol, Levsin, Urispas, Pro-Banthine).  Tricyclics such as Tofranil can be used.

Also, he mentioned an important difference between MSA and PD:  “In PD, there can be sympathetic enervation to the heart is impaired.  (36:48)  In fact, it’s almost gone.  This doesn’t affect the functioning of the heart.  This may be useful in distinguishing PD from MSA because in MSA and in vascular parkinsonism the heart is normal.  (38:10)  This can be useful but it’s not sensitive enough.”

And I will relay his warning about Reglan:  “Don’t ever let an MD put you on Reglan, which works well but is terrible for those with PD.”  I think this caution would apply to those dealing with atypical parkinsonism disorder as well because the problem with Reglan is that it depletes dopamine.

These are my notes from his presentation and his answers to the questions directed to him.  Of course it’s much better to watch the video yourself.

Robin


Robin’s notes from:

When Parkinson’s Interferes with Gastrointestinal, Urological, Sexual and Other Functions  (he starts speaking at 1:48)
Ron Pfeiffer, M.D., Neurology, University of Tennessee Health Science Center

Non-motor features of PD:
* abnormalities of sensation
* behavioral changes
* sleep disturbances
* abnormalities of respiratory function
* autonomic dysfunction –> the focus of his presentation
* fatigue

The autonomic nervous system might be called the automatic nervous system.  It handles functions we don’t have to think about including:
* gastrointestinal –> he’ll spend most of his time here
* cardiovascular
* urological
* sexual
* thermoregulatory
* respiratory

In PD, things go wrong with the autonomic nervous system.

Gastrointestinal (starts at 5:00) dysfunction was described by James Parkinson.  GI symptoms include:
* salivary excess
* dysphagia
* nausea
* decreased frequency of bowel movements
* defecatory dysfunction
* weight loss

It had been thought that GI dysfunction was due to problems in the substantia nigra (midbrain).  Braak proposes that PD changes start in two other areas of the brain:  the olfactory center and the medulla (brain stem).  The medulla affects the vagus nerve, which controls a lot of the autonomic system.

Within the GI system, there’s another nervous system that controls the gut.  This is called the enteric nervous system.  Braak found alpha-synuclein deposition in the stomach.  So maybe PD originates not in the brain but in the stomach!  Maybe PD is transported from the stomach to the brain via the vagus nerve.  Dopamine deficiency can also be found in the enteric nervous system.

Weight loss in PD occurs in 52%.  (11:10)  May precede diagnosis.  Average weight loss is 7.2 lbs. (but 22% lose > 28 lbs!).  Reason is unclear:  reduced energy intake (but calorie intake is similar) or increased energy expenditure?

Excess saliva is experienced by 70-78% of PDers.  Saliva production is actually decreased.  Reasons saliva accumulates:  decreased swallowing frequency and efficiency, tendency for mouth to be open, stooped posture.

Treatment of excess saliva:
* anticholinergics: but these can make saliva more tenacious and viscous; systemic administration probably best avoided; sublingual atropine ophthalmic solution; can cause urinary retention and memory problems; [his slide says this but he didn’t discuss it:  glycopyrrolate avoids CNS but not peripheral AEs] * intraparotid botox: but there’s risk of pharyngeal muscle weakness
* antiparkinson medication: to improve swallowing efficiency
* gum and hard candy: very useful in a social situation
* tympanic neurectomy: he doesn’t recommend this (dubious benefit)

Dysphagia in PD occurs in 30-82%, according to questionnaires.  MBS (modified barium swallow) shows *some* abnormality in 75-97% though patients may be clinically asymptomatic.  In MBS, a barium-laced liquid, pudding, and cookie are swallowed.  MBS views mouth and throat, not esophagus.  Any phase of swallowing may be affected.

Complications of dysphagia:  (17:18)
* some degree of aspiration is present in 15-56% of those with PD.  Not necessarily full scale aspiration.  Aspiration = something getting past vocal cords.
* clinically silent aspiration present in 15-33%.  Coughing or choking when eating may be a clue.
* any abnormality increases risk of pneumonia.
[his slide says this but he didn’t discuss it:  * one particular abnormality (vallecular residue) present in 88% of patients without dysphagia.]

Oropharyngeal dysfunction diagnosed by:
* MBS
* pharyngeal manometry
* electromyography
* videomanofluroometry

Esophageal dysfunction diagnosed by:
* videofluoroscopy
* endoscopy
* esophageal manometry

Other problems that can affect the esophagus but may have nothing directly to do with PD:  (18:20)
* Zenker’s diverticulum: food collects; bad breath is common; people cough up undigested food hours after eaten; can be treated surgically
* cricopharyngeal bar: muscle that doesn’t relax when swallowing; can be treated surgically
* anterior osteophytes: arthritic changes
* achalasia: enteric nervous system is damaged and constricts down

At 19:32 there’s a good slide and discussion of how to approach diagnosis of dysphagia.

GERD can also affect swallowing.

Nausea in PD occurs in 16% of unmedicated people with PD.  (20:50)
Bloating occurs in 43% of unmedicated people
Gastroparesis (impaired emptying of stomach) may be responsible

Gastroparesis symptoms:  early satiety, sense of bloating, nausea/vomiting, weight loss

If there’s gastroparesis, alternate medication delivery routes can be sought:
* subcutaneous:  apomorphine, lisuride  (used in Europe)
* enteral (jejunal):  levodopa  (used in Europe)
* sublingual:  selegiline
* transdermal:  rotigotine  (only briefly available in US)

Prokinetic drugs can improve gastric emptying:  (23:00)
* dopamine antagonists:  domperidone works the best; this med is not available in the US; “your cagey neurologist” can probably get this medication for you from Canada.  Don’t ever let an MD put you on Reglan, which works well but is terrible for those with PD.
* serotonin 5-HT4 agonists:  Cisapride, Tegaserod, Mosapride, Prucalopride, Renzapride.  None of these is available in the US currently because of potential cardiac injury.

A gastric pacemaker can be placed to treat severe gastroparesis.  This has not been studied in those with PD.

The small intestine has not been studied in PD.  The clinical consequences of small intestine dysfunction are unclear.  Could this lead to abdominal bloating?  Could this lead to altered nutrient absorption, thereby causing weight loss?

Constipation = colonic inertia.  Decreased bowel movement frequency.  (25:12)
Defecatory dysfunction is more common than constipation, though he’s not sure everyone has found that.

The Honolulu Asian Aging Study showed that people who had less than one BM per day had:
* twice the likelihood of getting PD as compared to someone who had one BM per day, and
* four times as likely to get PD as compared to someone who had two or more BMs per day.
Unclear if this means that the presence of PD was evident years before the symptoms or if decreased bowel frequency has something to do with the etiology of PD.

Colon transit time is prolonged in PD.  Occurs in about 80% of PD patients.  (27:20)

The first step to treating constipation should always be to increase the amount of fiber and fluid one consumes.  (28:48)  Americans almost universally have a fiber-deficient diet.  If adding fiber to the diet doesn’t work, try a supplement.  Eight glasses of fluid a day need to be consumed.  Add a stool softener if that helps.  Next step is Miralax, available OTC.  Can be taken as needed or daily.  Next step is another choice of osmotic laxative.  If all else fails, enemas can be used.  It’s wise to avoid irritating laxatives for fear of damaging the enteric nervous system with prolonged used.

Medications have been looked at to speed up colon transit time:  Cisapride, NT3, Tegaserod, Prucalopride, and Lubiprostone (Amitiza).  Of these, only Amitiza is available.  The others have been withdrawn due to toxicity.  A teacher of his recommends pyridostigmine for this problem.  Surgical treatment is available:  colectomy (removal of part of the colon).

Defecatory dysfunction occurs in 66% of PD patients.  This includes increased straining, painful defecation, and incomplete emptying.  Some muscles are supposed to relax and others contract when having a BM.  In PD, this doesn’t always happen.  There can be insufficient intra-abdominal pressure.  Underlying mechanisms may be due to bradykinesia, rigidity, and dystonia of the sphincters (off-period phenomenon).  You can be tested for this but the tests (including defecography and anorectal manometry) are somewhat exotic.  There really isn’t any proven treatment for this problem.

In PD, there can be sympathetic enervation to the heart is impaired.  (36:48)  In fact, it’s almost gone.  This doesn’t affect the functioning of the heart.  This may be useful in distinguishing PD from MSA because in MSA and in vascular parkinsonism the heart is normal.  (38:10)  This can be useful but it’s not sensitive enough.

Orthostatic hypotension (drop in BP when standing) occurs in 58% of people with PD — in 20% it produces symptoms, while in 38% it produces no symptoms.  Antiparkinson meds can magnify this problem.  Lightheadedness (progressing to fainting) is the typical sensation but there are many others that people don’t realize.  (39:10)  Other symptoms include:  vision problems, impaired thinking, headache in a coathanger distribution, lower back or rear-end ache (because muscles deprived of blood), fatigue or lethargy.

Postprandial hypotension (BP drops after meals) can be triggered by carbohydrates (most likely culprit).  Sitting or standing may exacerbate.  Same symptoms as OH.  May develop within 15 minutes of eating, and may persist up to 3 hours.  In a normal person, eating a meal doesn’t cause BP to drop.  Deal with this by eating smaller meals more frequently.  Or rest/relax after eating until the problem passes.

Urinary dysfunction occurs in 27-39% of those with PD, according to newer studies.  (41:10)  Troublesome incontinence is in 15%.  Symptoms correlate with stage of disease.  Two types:  irritative (most common; consists of overactive bladder contraction) and obstructive.  Characteristics of irritative bladder are:  frequent urination, nighttime urination, urination of small amounts, urgency, and “urge” type incontinence.

To treat irritative symptoms, he prefers the newer anticholinergics (Sanctura, Enablex, Vesicare — the first two are unlikely to cross the blood-brain barrier) compared to the older ones (Ditropan, Detrol, Levsin, Urispas, Pro-Banthine).  Tricyclics such as Tofranil can be used.

Obstructive urinary symptoms include hesitancy and weak urinary stream.  May develop overflow incontinence.  Treatment is more difficult.  Intermittent catheterization is probably going to be the most effective treatment.  (44:05)

Bladder ultrasound can be a useful test to differentiate if this is an overactive or underactive bladder.

Question:  Will a colectomy have an impact on PD symptoms?  (45:45)
Answer:  I don’t think so.

Question:  Can drugs like Flomax be used in women with PD?
Answer:  I don’t think so.

Question:  Any relationship between ulcerative colitis and PD?
Answer:  I’m not aware of any.  Ulcerative colitis is an auto-immune disease.  PD is not an immune-related disease.

Question:  Is there any relationship between PD and sigmoid volvulus?
Answer:  It’s very rare and has to be treated surgically.

Question:  You mentioned injections in Europe to treat nausea and bloating. (48:22)
Answer:  Apomorphine infusions can be used to deliver meds if there’s gastroparesis but this med does not to treat gastroparesis itself.

Question:  What about diarrhea?  (51:12)
Answer:  Generally diarrhea isn’t a problem with PD per se.  Although if a person has severe constipation and gets impacted, eventually stool will liquify and go around the impaction area, and cause diarrhea.  Also, some meds can cause diarrhea.

Question:  My voice is raspy.  It feels tight around my throat.  What is this from?  (51:56)
Answer:  The most common speech problem in PD is a soft, breathy voice because people are not pushing enough air past the vocal cords or the vocal cords may not be closing tightly.  When you say “raspy,” this might be that the vocal cords are spasming.  Lee Silverman Speech Therapy has been developed for those with PD.

Question:  Should someone with PD who has frequent UTIs keep getting meds or does cranberry juice work?
Answer:  If you get an infection, you need antibiotics.  Cranberry juice may prevent UTIs.  If someone continues to get infections, a urologist may put him/her on chronic antibiotic therapy as a preventive measure.

Question:  What about sexual dysfunction?
Answer:  This is common but doesn’t get talked about much.  70% of so men have ED.  ED drugs can drop BP.  44% of men have decreased libido.  Much higher percentage of women have decreased libido.  Not much treatment for decreased libido.

Audience Member Comment:  PDers who drool give good wet kisses.

Question:  Is gall bladder inflammation related to PD?
Answer:  Nothing written about this.

Question:  Is there a portable electrical device to improve bowel function?
Answer:  I’m not aware of anything.

Question:  Bee stings caused my PD symptoms to dissipate.  Twice.  Can you speak to this?  France has been studying this.
Answer:  I’m not aware of anything in the literature about this.  Presumably this is affecting the body’s immune system.

Question:  How does Viagra affect PD or vice versa?
Answer:  Drugs like Viagra can be effective in treating ED but there can be a tendency for these drugs to cause the BP to drop.  It’s not cool to faint when you are trying to get other things done.  If you already have OH, you should probably stay away from these drugs.

 

Experimental AD drug that fights tau (not beta-amyloid)

There’s a lot of news coming out of Chicago during the big Alzheimer’s Disease conference there this week. The first part of this news article on an experimental drug fighting the protein tau is what caught my eye. Tau is the key protein involved in PSP and CBD. The article briefly mentions a second experimental tau-fighting drug that was used on those with mild cognitive impairment. The remainder of the article mentions Flurizan, where the development of this beta-amyloid-fighting drug has been halted, and the Elan/Wyeth experimental drug bapineuzumab. To my knowledge, beta-amyloid is NOT an issue in PSP or CBD. I read this article in the Miami Herald.

http://www.miamiherald.com/living/healt … 21968.html

Experimental Alzheimer’s drug shows early promise
Posted on Tue, Jul. 29, 2008
By MARILYNN MARCHIONE
AP Medical Writer

CHICAGO — For the first time, an experimental drug shows promise for halting the progression of Alzheimer’s disease by taking a new approach: breaking up the protein tangles that clog victims’ brains.

The encouraging results from the drug called Rember, reported Tuesday at a medical conference in Chicago, electrified a field battered by recent setbacks. The drug was developed by Singapore-based TauRx Therapeutics.

Even if bigger, more rigorous studies show it works, Rember is still several years away from being available, and experts warned against overexuberance. But they were excited.

“These are the first very positive results I’ve seen” for stopping mental decline, said Marcelle Morrison-Bogorad, director of Alzheimer’s research at the National Institute on Aging. “It’s just fantastic.”

The federal agency funded early research into the tangles, which are made of a protein called tau and develop inside nerve cells.

For decades, scientists have focused on a different protein – beta-amyloid, which forms sticky clumps outside of the cells – but have yet to get a workable treatment.

The drug is in the second of three stages of development, and scientists are paying special attention to potential treatments because of the enormity of the illness, which afflicts more than 26 million people worldwide and is mushrooming as the population ages.

The four Alzheimer’s drugs currently available just ease symptoms of the mind-robbing disease.

TauRx’s chief is Claude Wischik, a biologist at the University of Aberdeen in Scotland who long has done key research on tau tangles and studies suggesting that Rember can dissolve them.

He is an “esteemed biologist,” and the research “comes with his credibility attached to it,” said Dr. Sam Gandy of Mount Sinai School of Medicine in New York. He heads the scientific advisory panel of the Alzheimer’s Association.

In the study, 321 patients were given one of three doses of Rember or dummy capsules three times a day. The capsules containing the highest dose had a flaw in formulation that kept them from working, and the lowest dose was too weak to keep the disease from worsening, Wischik said.

However, the middle dose helped, as measured by a widely used score of mental performance.

“The people on placebo lost an average of 7 percent of their brain function over six months whereas those on treatment didn’t decline at all,” he said.

After about a year, the placebo group had continued to decline but those on the mid-level dose of Rember had not. At 19 months, the treated group still had not declined as Alzheimer’s patients have been known to do.

Two types of brain scans were available on about a third of participants, and they show the drug was active in brain areas most affected by tau tangles, Wischik said.

“This is suggestive data,” not proof, Wischik warned. The company is raising money now for another test of the drug to start next year.

The main chemical in Rember is available now in a different formulation in a prescription drug sometimes used since the 1930s for chronic bladder infections – methylene blue. However, it predates the federal Food and Drug Administration and was never fully studied for safety and effectiveness, and not in the form used in the Alzheimer’s study, Wischik and other doctors cautioned.

On Monday at the International Conference on Alzheimer’s Disease, other researchers reported encouraging results from a test of a different experimental drug that also targets tau tangles. That drug, by British Columbia-based Allon Therapeutics Inc., was tested in people with an Alzheimer’s precursor, mild cognitive impairment.

The tau-drug results are in stark contrast to the flop of Flurizan, which was aimed at blocking enzymes that form the beta-amyloid clumps. Myriad Genetics announced in June that it would abandon development of Flurizan after the failure. Full results were presented at the conference Tuesday.

Also, fuller results were given from a closely watched test of bapineuzumab, an experimental drug that aims to enlist the immune system to clear out the sticky brain clumps.

Its developers – New Jersey-based Wyeth and the Irish company Elan Corp. PLC – previously announced that the 240-patient study missed its main goal of improving patients’ mental performance at 18 months.

But the company found a silver lining – the drug appeared to help the roughly 60 percent of people in the study who did not have a gene that scientists think makes Alzheimer’s disease more severe.

The results back up the company’s claims of potential effectiveness in some patients, but now there are concerns about possible side effects. Twelve cases of a type of brain swelling occurred in those on bapineuzumab and none in the placebo group. The swelling caused few if any symptoms, company scientists said, but outside experts said it may have contributed to other side effects.

Those were two or more times more common in patients on bapineuzumab than people given the dummy drug. For example, cases of anxiety occurred in 11 percent versus 4 percent on placebo; paranoia, 7 versus 1 percent. Other complaints were vomiting, high blood pressure, weight loss, and back pain.

Three deaths occurred among the 124 patients given bapineuzumab, but they were not related to the drug, said Dr. Sid Gilman of the University of Michigan, who headed the study’s data safety monitoring board. One death was due to pneumonia and two others to worsening Alzheimer’s disease.

Investors reacted to the news by driving down Wyeth’s shares $5.01, or 11.1 percent, in after-hours trading.

Wyeth and Elan have already said they will move on to late-stage testing of bapineuzumab in more than 4,000 patients.

“A Short Stay in Switzerland” movie about death with dignity (and PSP) – coming soon

This is an excerpt from an article in a London newspaper about a BBC movie that begins filming soon.  It is called “A Short Stay in Switzerland.”  The movie is about Dr. Anne Turner who went to Switzerland to die with dignity.  Dr. Turner had progressive supranuclear palsy.  Her husband died with multiple system atrophy.  Actress Julie Walters plays Dr. Turner.

Robin

——————-

www.dailymail.co.uk/tvshowbiz/article-1036129/BAZ-BAMIGBOYE-Ralph-Fiennes-Nicole-Kidman-Julie-Walters–more.html

Julie honours a woman who died with dignity
Daily Mail (London), July 19, 2008

Julie Walters, in the groove with hit film musical Mamma Mia!, is taking on a real-life role that will be the subject of passionate debate.

Walters will portray Dr Anne Turner, the former medical practitioner from Bath who hit the headlines in early 2006 when she gave notice of her intention to end her life by means of an assisted suicide.

Rehearsals begin next month in London on the BBC1 TV film called A Short Stay In Switzerland, a factually-inspired drama written by playwright Frank McGuinness.

Simon Curtis, the director, said McGuinness’s screenplay sensitively explores the final 18 months of Dr Turner’s life until she and her three children travel to a clinic in Zurich where arrangements had been made for her to die with dignity, which she argued ‘should be everybody’s right’.

It’s a highly emotive topic but, Curtis noted, the combination of McGuinness’s script and Julie Walters’s acting should be able to make it palatable for TV audiences.

Dr Turner died on January 26, 2006, a day before her 67th birthday.  She had been diagnosed with Progressive Supranuclear Palsy (PSP), a neurological degenerative disease.

Her husband had died in 2002 of Multiple System Atrophy (MSA). Sufferers lose their sense of balance and are unable to talk, swallow or blink.

Curtis, who directed the acclaimed Cranford serial with Judi Dench and Eileen Atkins, will meet Dr Turner’s family next week.

Her son and daughters have already collaborated with McGuinness and producers Liz Trubridge and Ruth Caleb on the screenplay.

‘The family has been very supportive, which is important in a drama of this nature,’ Curtis observed.

‘They’re a loving family and in difficult times you find glimpses of warmth, happiness, love and humour.’

He added that Walters has what he called ‘that extra ingredient the public responds to; Dame Judi has that, too.

‘The audience love to go on the journey she takes them on’.

A Short Stay In Switzerland will shoot in London for four weeks, with a brief location in Zurich.

 

CJD-like Dementia in US Called “PSPr”

Thought you might want to know that a US scientist has identified a new dementia in the US, and given it a name that includes “PSP.” The new dementia is a prion disorder, is similar to CJD, Creutzfeldt-Jakob disease — a “fast advancing dementia but with additional loss of movement and speech.” Confusingly, the name given to the disorder is “PSPr” for protease-sensitive prionopathy I read about this on a PSP-related Yahoo!Group tonight. What follows is a MedicalNews Today article as well as the abstract from the scientific journal about this new dementia.
Robin

http://www.medicalnewstoday.com/articles/114614.php

New Fatal CJD-Like Dementia Discovered In America
MedicalNews Today
10 Jul 2008

A new dementia that is distinct from but resembles known forms of CJD, Creutzfeldt-Jakob disease, has been discovered in America, affecting 16 people, 10 of whom have died after gradually losing their mental and motor functions and being unable to think, speak or move.

Yesterday’s issue of New Scientist reported that Pierluigi Gambetti, the director of the US National Prion Disease Pathology Surveillance Center based at Case Western Reserve University in Cleveland, Ohio, said nobody knows how the disease starts or spreads, or how many people may have it.

Gambetti and colleagues wrote a paper on the discovery of the disease, called PSPr (for protease-sensitive prionopathy), in a paper that was published online in the Annals of Neurology on 20th June 2008.

Gambetti said he believed the disease had been around for some time and may have been mistaken for other forms of dementia. The 16 cases include the 11 he described in the paper and another 5 that have since been diagnosed. Ten of the 16 patients have died of the disease. Their brains had the trademark damage that is normally associated with CJD (note this is not variant or vCJD that is linked to mad cow disease or BSE), except that in the case of PSPr, Gambetti and colleagues suggest the cause is genetic.

According to BBC news, experts in the UK are now checking records to see how many cases there may be in the UK, where there are between 50 and 100 cases of so-called sporadic CJD every year.

A representative of the UK’s National CJD Surveillance Unit, in Edinburgh, Dr Mark Head, said they were reviewing cases of sporadic CJD for clues that there might be some that are really PSPr. He also said it may mean there are other prion disease genes waiting to be discovered.

Sporadic CJD has no known cause, unlike the BSE-linked vCJD that is contracted from eating infected cows’ brains or spinal cord tissue.

In the US, PSPr came to light when cases were referred to CJD surveillance centers because the symptoms appeared to be CJD-like (fast advancing dementia but with additional loss of movement and speech). But tests for CJD proved negative.

Yet post mortems on the patients who died showed the familiar sponginess in the brain tissue that results when misshapen brain proteins or “prions” accumulate in the brain.

Gambetti suggested there might be a genetic link because the patients all had a family history of dementia but did not carry they CJD gene.

In the paper published earlier this year, Gambetti and colleagues reported their investigation of 11 cases at the National Prion Disease Pathology Surveillance Center for clinical, histopathological, immunohistochemical, genotypical, and prion protein (PrP) characteristics.

They wanted to report on what they believed to be a new form of prion disease where like the more common prion diseases there was a misshapen prion protein, but there was a difference in that the protein was sensitive to protease digestion.

In their conclusion they wrote that their histological, immunochemical, physicochemical and genetic investigation indicated that:

“This is a previously unidentified type of disease involving the PrP [prion protein], which we designated protease-sensitive prionopathy (or PSPr). Protease-sensitive prionopathy is not rare among prion diseases, and it may be even more prevalent than our data indicate because protease- sensitive prionopathy cases are likely also to be classified within the group of non-Alzheimer’s dementias.”

“A novel human disease with abnormal prion protein sensitive to protease.”
Pierluigi Gambetti, Zhiqian Dong, Jue Yuan, Xiangzhu Xiao, Mengjie Zheng, Amer Alshekhlee, Rudy Castellani, Mark Cohen, Marcelo A. Barria, D. Gonzalez-Romero, Ermias D. Belay, Lawrence B. Schonberger, Karen Marder, Carrie Harris, James R. Burke, Thomas Montine, Thomas Wisniewski, Dennis W. Dickson, Claudio Soto, Christine M. Hulette, James A. Mastrianni, Qingzhong Kong, Wen-Quan Zou.
Annals of Neurology, Volume 63 Issue 6, Pages 697 – 708.
Published Online: 20 Jun 2008.
DOI: 10.1002/ana.21420

Source: BBC, New Scientist, Annals of Neurology abstract.

Written by: Catharine Paddock, PhD
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Here’s the abstract of the article in the Annals of Neurology:

A novel human disease with abnormal prion protein sensitive to protease

Pierluigi Gambetti, MD 1 *, Zhiqian Dong, PhD 1, Jue Yuan, BA 1, Xiangzhu Xiao, PhD 1, Mengjie Zheng, PhD 1, Amer Alshekhlee, MD 1, Rudy Castellani, MD 2, Mark Cohen, MD 1, Marcelo A. Barria, PhD 3, D. Gonzalez-Romero, PhD 3, Ermias D. Belay, MD 4, Lawrence B. Schonberger, MD, MPH 4, Karen Marder, MD 5, Carrie Harris, BA 1, James R. Burke, MD, PhD 6, Thomas Montine, MD 7, Thomas Wisniewski, MD 8, Dennis W. Dickson, MD 9, Claudio Soto, PhD 3, Christine M. Hulette, MD 10, James A. Mastrianni, MD, PhD 11, Qingzhong Kong, PhD 1, Wen-Quan Zou, MD, PhD 1 *

1Institute of Pathology, Case Western Reserve University, Cleveland, OH
2Department of Pathology, University of Maryland, Baltimore, MD
3Department of Neurology, Neuroscience and Cell Biology, George and Cynthia Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX
4Centers for Disease Control and Prevention, Atlanta, GA
5Department of Neurology, Columbia University, New York, NY
6Department of Medicine, Division of Neurology, Duke University, Durham, NC
7Harborview Medical Center, University of Washington, Seattle, WA
8Department of Neurology, New York University, New York, NY
9Department of Neuropathology, Mayo Clinic College of Medicine, Jacksonville, FL
10Department of Pathology, Duke University, Durham, NC
11Department of Neurology, University of Chicago, Chicago, IL

email: Pierluigi Gambetti ([email protected]) Wen-Quan Zou ([email protected])

*Correspondence to Pierluigi Gambetti, Institute of Pathology, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106
*Correspondence to Wen-Quan Zou, Institute of Pathology, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106

Funded by:
NIH; Grant Number: AG14359, AG08702, NS049173
Centers for Disease Control and Prevention; Grant Number: CCU 515004
Britton Fund
CJD Foundation

Abstract

Objective
To report a novel prion disease characterized by distinct histopathological and immunostaining features, and associated with an abnormal isoform of the prion protein (PrP) that, contrary to the common prion diseases, is predominantly sensitive to protease digestion.

Methods
Eleven subjects were investigated at the National Prion Disease Pathology Surveillance Center for clinical, histopathological, immunohistochemical, genotypical, and PrP characteristics.

Results
Patients presented with behavioral and psychiatric manifestations on average at 62 years, whereas mean disease duration was 20 months. The type of spongiform degeneration, the PrP immunostaining pattern, and the presence of microplaques distinguished these cases from those with known prion diseases. Typical protease-resistant PrP was undetectable in the cerebral neocortex with standard diagnostic procedures. After enrichment, abnormal PrP was detected at concentrations 16 times lower than common prion diseases; it included nearly 4 times less protease-resistant PrP, which formed a distinct electrophoretic profile. The subjects examined comprised about 3% of sporadic cases evaluated by the National Prion Disease Pathology Surveillance Center. Although several subjects had family histories of dementia, no mutations were found in the PrP gene open reading frame.

Interpretation
The distinct histopathological, PrP immunohistochemical, and physicochemical features, together with the homogeneous genotype, indicate that this is a previously unidentified type of disease involving the PrP, which we designated protease-sensitive prionopathy (or PSPr). Protease-sensitive prionopathy is not rare among prion diseases, and it may be even more prevalent than our data indicate because protease-sensitive prionopathy cases are likely also to be classified within the group of non-Alzheimer’s dementias. Ann Neurol 2008;63:697-708
——————————————————————————–
Received: 5 November 2007; Revised: 1 April 2008; Accepted: 4 April 2008